Clinical trials: Vaccine-Preventable Diseases
Vaccine-Preventable Diseases, Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
- Trial name
- NCT06137755
- Testing
- CVI-VZV-001, Shingrix
- Where
- 2 sites in South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Hepatitis B, Vaccination; Infection
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs…
- Conditions
- Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine
- Trial name
- IRHBRVD (NCT04970836)
- Testing
- recombinant hepatitis B vaccine
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Meningococcal Disease; Meningococcal Meningitis
Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years
The sample size of this study is 200 participants, aiming to evaluate the protective effect after vaccination with quadrivalent meningococcal polysaccharide vaccine in the 13-15 age group, and to provide scientific evidence and…
- Trial name
- NCT07885371
- Testing
- MPSV-ACYW
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Shingles, Herpes Zoster
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT06569823
- Testing
- Z-1018, Shingrix
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
HPV Infection, Vaccine Preventable Disease
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to…
- Trial name
- Add-Vacc (NCT04953130)
- Testing
- Gardasil® HPV vaccine
- Where
- Tanzania
- Volunteers
- 10,400 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV).
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Trial name
- NCT06098690
- Testing
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Human Papilloma Virus, Vaccine-Preventable Diseases
Hashtag HPV: HPV Vaccine Twitter Education Program
Parents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts…
- Trial name
- NCT05204030
- Testing
- HPV Twitter Education Program - Narrative, HPV Twitter Education Program - Non-Narrative
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Arkansas, Fayetteville
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
Pertussis, Diphtheria
Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old
Pertussis remains a major global public health problem. In Thailand, pertussis vaccination is recommended during pregnancy at 20-32 weeks' gestation, together with routine childhood diphtheria-tetanus-pertussis vaccination…
- Conditions
- Pertussis, Diphtheria, Tetanus, Vaccine-Preventable Diseases
- Trial name
- M-PRIME (NCT07621341)
- Testing
- Maternal TdaP2gen vaccine, Infant Acellular Pertussis-containing Vaccine, Infant Whole-cell Pertussis-containing Vaccine
- Where
- Thailand
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Hepatitis A, Hepatitis A Virus
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand's…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- HAV-2 (NCT06978621)
- Testing
- Inactivated hepatitis A vaccine (I-HAV)
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Hepatitis A, Hepatitis A Virus
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Hepatitis A virus (HAV) remains a common infection among Thai children. Two types of HAV vaccines are available in Thailand: an inactivated vaccine (I-HAV, administered in two doses 6 months apart) and a live-attenuated vaccine…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- NCT07032610
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
HPV, Vaccine-Preventable Diseases
Playing Game to Learn About Children's Vaccine Project
This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth…
- Trial name
- NCT05984849
- Testing
- vaccination game
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Michigan State University
HPV Infection, Vaccine-Preventable Diseases
Game-Based Intervention to Promote HPV Vaccination
This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures…
- Trial name
- NCT06162676
- Testing
- HPV game
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Michigan State University
COVID-19, Vaccine Adverse Reaction
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases
- Trial name
- Plus_Booster (NCT05283902)
- Testing
- ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
- Where
- Brazil
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
Preventable Disease, Vaccine
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
The goal of this pilot demonstration and evaluation project is to determine the acceptability and feasibility of a co-payment model among the public and providers and assess whether a co-payment model in community pharmacies in…
- Trial name
- NCT06489964
- Testing
- Co-payment Model - Step 1, Co-payment Model - Step 2, Co-payment Model - Step 3
- Where
- 2 sites in Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Vaccine-Preventable Diseases, COVID-19 Pandemic
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
COVID-19 vaccines are available to children over six months, and these vaccines are powerful tools against this catastrophic pandemic.
- Conditions
- Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior, Health Knowledge, Attitudes, Practice
- Trial name
- NCT06036134
- Testing
- Baseline surveys, Digital Storytelling Intervention, Information Control Intervention
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Healty Volunteers, Preventable Disease, Vaccine
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
This is a phase 2,prospective double-blind, randomized, parallel-group study with the aim to demonstrate non-inferiority, in terms of immunogenicity, between the wet formulation and a newly developed partially dried formulation…
- Trial name
- NCT05178134
- Testing
- Etvax
- Where
- Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Plague, Pneumonic, Plague
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
- Conditions
- Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
- Trial name
- NCT05506969
- Testing
- rF1V-1018, rF1V vaccine
- Where
- 6 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation